Colchicine Online



How and where to order Colchicine 0.5 mg tablets or capsules online on the Coastal Interventional Pain Associates website:

Shop:DFH PHARMACY
Stores:PHARMA DOCTOR
Prices:from $0.46 per pill
Discount:10% coupon: DFHDCC
Forms:500 mcg tablets
Quantity:30-360 pills
Type:Colchicine brand, Colcrys generic
Payment:Visa, Mastercard, AmEx, eCheck, Bitcoin
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Colchicine (trade names include Colcrys, Celogot, Colchicina, Colchigen, Colchis, Colgout, Lengout) is an antigout medication, alkaloid of Colchicum autumnale L., Liliaceae from preparations with no effect on uric acid metabolism pharmacological froup. This medicine is prescribed for the treatment of gout, joint pain and swelling due to attacks of acute gouty arthritis. It works as beta-tubulin interactor: colchicine may affect certain proteins in the body, which may relieve gout symptoms. The drug is indicated to treat Familial Mediterranean fever; as a component of homeopathic medicines; for prevention of atrial fibrillation after cardiac surgery; and in therapy of other diseases and medical conditions, including Behcet's disease, Paget's disease, dermatitis herpetiformis, pseudogout, amyloidosis, calcinosis, scleroderma, pericarditis, vasculitides, spondyloarthropathies, atherosclerosis, chronic coronary disease, pulmonary fibrosis, biliary and hepatic cirrhosis. Colchicine is also has botanical use in plant breeding.


Colchicine tablets 0.5 mg


Related medications:

  • Acetaminophen, Methocarbamol (Robaxacet)
  • Azathioprine (Imuran)
  • Celecoxib (Celebrex)
  • Cinchophen (Rhematan)
  • Dexamethasone (Decadron)
  • Diclofenac (Voltaren)
  • Divalproex (Depakote)
  • Etodolac (Lodine)
  • Etoricoxib (Arcoxia)
  • Ibuprofen (Motrin)
  • Indomethacin (Indocin)
  • Leflunomide (Arava)
  • Mefenamic Acid (Ponstel)
  • Meloxicam (Mobic)
  • Methotrexate (Rheumatrex)
  • Methylprednisolone (Medrol)
  • Naproxen (Naprosyn)
  • Piroxicam (Feldene)
  • Prednisolone (Millipred)
  • Prednisone (Deltasone)
  • Probenecid (Probalan)


    Pharmacological and medical categories:

  • Anesthetics
  • Antigout medicines
  • Cardiovascular medications
  • Hyperuricemia and gout preparations
  • Pain relief drugs


    ATC codes:

  • M - Musculo-skeletal system
  • M04 - Antigout preparations
  • M04A - Antigout preparations
  • M04AC - Preparations with no effect on uric acid metabolism
  • M04AC01 - Colchicine


    ICD-10 codes:

  • Amyloidosis - E85
  • Chronic ischemic heart disease - I25
  • Acute pericarditis - I30
  • Atrial fibrillation and flutter - I48
  • Atherosclerosis - I70
  • Other disorders of arteries and arterioles - I77
  • Other interstitial pulmonary diseases - J84
  • Pulmonary fibrosis, unspecified - J84.10
  • Fibrosis and cirrhosis of liver - K74
  • Other bullous disorders - L13
  • Dermatitis herpetiformis - L13.0
  • Other localized connective tissue disorders - L94
  • Localized scleroderma [morphea] - L94.0
  • Calcinosis cutis - L94.2
  • Vasculitis limited to skin, not elsewhere classified - L95
  • Intraoperative and postprocedural complications and disorders of circulatory system, not elsewhere classified - I97
  • Autoinflammatory syndromes - M04
  • Periodic fever syndromes - M04.1
  • Gout - M10
  • Other crystal arthropathies - M11
  • Other joint disorder, not elsewhere classified - M25
  • Effusion, unspecified joint - M25.40
  • Pain in unspecified joint - M25.50
  • Other systemic involvement of connective tissue - M35
  • Behcet's disease - M35.2
  • Other inflammatory spondylopathies - M46
  • Unspecified inflammatory spondylopathy, site unspecified - M46.90
  • Osteitis deformans [Paget's disease of bone] - M88


    Indications and usage:

    Colcrys (Colchicine) tablets are an alkaloid indicated for:

  • Prophylaxis and treatment of gout flares in adults.
  • Familial Mediterranean fever (FMF) in adults and children 4 years or older.

    Colchicine is not an analgesic medication and should not be used to treat pain from other causes.


    Contraindications:

    Patients with renal or hepatic impairment should not be given Colcrys in conjunction with P-gp or strong CYP3A4 inhibitors. In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.


    Dosage and administration:

    Gout flares

  • Prophylaxis of gout flares: 0.6 mg of Colcrys (Colchicine) tablets once or twice daily in adults and adolescents older than 16 years of age. Maximum dose 1.2 mg/day.
  • Treatment of gout flares: 1.2 mg (two tablets) at the first sign of a gout flare followed by 0.6 mg (one tablet) one hour later.

    FMF

    Adults and children older than 12 years 1.2 2.4 mg; children 6 to 12 years 0.9 1.8 mg; children 4 to 6 years 0.3 1.8 mg.

  • Give total daily dose in one or two divided doses.
  • Increase or decrease the dose as indicated and as tolerated in increments of 0.3 mg/day, not to exceed the maximum recommended daily dose.

    Colchicine tablets are administered orally without regard to meals.


    Overdosage:

    The exact dose of Colchicine (Colcrys) that produces significant toxicity is unknown. Fatalities have occurred after ingestion of a dose as low as 7 mg over a four-day period, while other patients have survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder toxicities such as gastrointestinal symptoms, whereas those who took 0.5 to 0.8 mg/kg had more severe reactions such as myelosuppression. There was 100% mortality in those who ingested more than 0.8 mg/kg.

    The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen. Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multiorgan failure and its consequences. Death is usually a result of respiratory depression and cardiovascular collapse. If the patient survives, recovery of multiorgan injury may be accompanied by rebound leukocytosis and alopecia starting about one week after the initial ingestion.

    Treatment of colchicine poisoning should begin with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by dialysis.


    Warnings and precautions:

  • Fatal overdoses have been reported with colchicine in adults and children. Keep Colcrys (Colchicine) pills out of the reach of children.
  • Blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction P-gp and/or CYP3A4 inhibitors: coadministration of colchicine with P-gp and/or strong CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity: myotoxicity including rhabdomyolysis may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of Colcrys.


    Adverse reactions, side effects:

  • Prophylaxis of gout flares: the most commonly reported adverse reaction of colchicine tablets in clinical trials for the prophylaxis of gout was diarrhea.
  • Treatment of gout flares: the most common adverse reactions reported in the clinical trial for gout were diarrhea (23%) and pharyngolaryngeal pain (3%).
  • FMF: most common adverse reactions (up to 20%) are abdominal pain, diarrhea, nausea and vomiting. These effects are usually mild, transient and reversible upon lowering the dose.

    To report suspected adverse reactions of Colcrys (Colchicine) tablets, contact Takeda Pharmaceuticals company or your local FDA.


    Drug interactions:

    Coadministration of P-gp and/or CYP3A4 inhibitors (e.g., clarithromycin or cyclosporine) have been demonstrated to alter the concentration of colchicine. The potential for drug-drug interactions must be considered prior to and during therapy. See full prescribing information for a complete list of reported and potential interactions.


    Use in specific populations:

  • In the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required for treatment of gout flare, prophylaxis of gout flare and FMF, but patients should be monitored closely.
  • In patients with severe renal impairment for prophylaxis of gout flares, the starting dose should be 0.3 mg/day for gout flares, no dose adjustment is required, but a treatment course should be repeated no more than once every two weeks. In FMF patients, start with 0.3 mg/day, and any increase in dose should be done with close monitoring.
  • In patients with severe hepatic impairment, a dose reduction may be needed in prophylaxis of gout flares and FMF patients; while a dose reduction may not be needed in gout flares, a treatment course should be repeated no more than once every two weeks.
  • For patients undergoing dialysis, the total recommended colchicine dose for prophylaxis of gout flares should be 0.3 mg given twice a week with close monitoring. For treatment of gout flares, the total recommended dose should be reduced to 0.6 mg (one tablet) x 1 dose and the treatment course should not be repeated more than once every two weeks. For FMF patients, the starting dose should be 0.3 mg/day and dosing can be increased with close monitoring.
  • Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
  • Nursing mothers: caution should be exercised when administered to a nursing woman.
  • Geriatric use: the recommended dose of colchicine should be based on renal function.


    Patient counseling information:

    Dosing instructions

    Patients should be advised to take Colcrys (Colchicine) tablets as prescribed, even if they are feeling better. Patients should not alter the dose or discontinue treatment without consulting with their doctor. If a dose of this medication is missed:

  • For treatment of a gout flare when the patient is not being dosed for prophylaxis, take the missed dose as soon as possible.
  • For treatment of a gout flare during prophylaxis, take the missed dose immediately, wait 12 hours, then resume the previous dosing schedule.
  • For prophylaxis without treatment for a gout flare, or FMF, take the dose as soon as possible and then return to the normal dosing schedule. However, if a dose is skipped the patient should not double the next dose.

    Fatal overdose

    Instruct patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. Colcrys should be kept out of the reach of children.

    Blood dyscrasias

    Patients should be informed that bone marrow depression with agranulocytosis, aplastic anemia and thrombocytopenia may occur with Colchicine (Colcrys).

    Drug and food interactions

    Patients should be advised that many drugs or other substances may interact with Colcrys (Colchicine) pills and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking and check with their healthcare provider before starting any new medications, particularly antibiotics.

    Patients should also be advised to report the use of nonprescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not be consumed during Colcrys treatment.

    Neuromuscular toxicity

    Patients should be informed that muscle pain or weakness, tingling or numbness in fingers or toes may occur with colchicine alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue Colcrys and seek medical evaluation immediately.


    Pregnancy categories:

  • D - Australia
  • C - United States (Risk cannot be ruled out)


    Salts and other forms:

  • Colchicine Base
  • Colchicine crystallized


    Synonyms, international and chemical names:

  • 7-Alpha-H-Colchicine
  • Benzo(a)Heptalen-9(5H)-one
  • Coilcicin
  • Colchicin
  • Colchicina
  • Colchicine cristallise
  • Colchicinum
  • Colhicine
  • Colquicina
  • Coltchicene
  • Kolchicin
  • Kolchicyna
  • Kolhicin
  • Kolkisiini
  • Kolkisina
  • Kolsisin


    Brands, generics, trade names:

  • Celogot - Celogen Pharma
  • Colchicin - Agepha, Pharbaco
  • Colchicina - Sanitas Laboratorio Chimico Farmaceutico
  • Colchicine - Abbott, Boots, Stada, Watson Pharmaceuticals
  • Colchicinum - Boiron, Dolisos
  • Colchicum - Weleda
  • Colchigen - Gen Pharma
  • Colchin - Greenpharma Quimica e Farmaceutica
  • Colchiquim - Quimica y Farmacia
  • Colchis - Apsen Farmaceutica
  • Colcine - Fascino Pharmacy Groups, Pharmahof
  • Colcrys - Takeda Pharmaceutical
  • Colgout - Aspen
  • Coloxvis - NIC Pharma
  • Goutnil - Inga Laboratories
  • Jamp-Colchicine - Jamp Pharma
  • Lengout - Aspen Pharmacare
  • Prochic - Millimed
  • Zycolchin - Zydus Cadila


    APIs used in medicine in combinations with colchicine:


  • Acetanilide
  • Allopurinol
  • Atropine
  • Belladonna
  • Caffeine
  • Calcium Phosphate
  • Dicyclomine
  • Lactic Acid
  • Magnesium Phosphate Dibasic
  • Nitroglycerin
  • Phenacetin
  • Phenylbutazone
  • Piperazine
  • Podophyllin
  • Potassium Iodide
  • Probenecid
  • Quinine
  • Theobromine


    Here is a list of popular medications containing colchicine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Colchicina Lirca
  • Tablets, Film-Coated; Oral; Colchicine 1 mg
  • Pharmafar
  • Colchicinum
  • Drops; Oral; Colchicine 3 dh
  • Drops; Oral; Colchicine 6 dh
  • Globules; Oral; Colchicine 6 dh
  • Granules; Oral; Colchicine 6 dh
  • Tablets; Oral; Colchicine 3 dh
  • Boiron
  • Colchiquim
  • Tablets; Oral; Colchicine 0.5 mg
  • Tablets; Oral; Colchicine 1 mg
  • Quimica y Farmacia
  • Colcrys
  • Tablets, Film-Coated; Oral; Colchicine 0.6 mg
  • Takeda Pharmaceutical
  • AR Holding
  • Mutual Pharmaceuticals
  • Colgout
  • Tablets, Film-Coated; Oral; Colchicine 0.5 mg
  • Aspen
  • Primal Chemical
  • Goutnil
  • Tablets; Oral; Colchicine 0.5 mg
  • Inga Laboratories
  • Ambica International Trading Corporation
  • Pahang Pharmacy
  • Zycolchin
  • Tablets; Oral; Colchicine 0.5 mg
  • Zydus Cadila



  • References:

  • Colchicine main article on Wikipedia: https://en.wikipedia.org/wiki/Colchicine
  • Colchicine compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Colchicine
  • Colchicine medicine on DrugBank: https://go.drugbank.com/drugs/DB01394
  • Colchicine FAQ on MedlinePlus (revised 04/15/2019): https://medlineplus.gov/druginfo/meds/a682711.html
  • Colcrys (Colchicine) film-coated tablets drug label on DailyMed (revised April 28, 2021): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Ascend Colchicine tablets drug label on DailyMed (revised February 5, 2021): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Colchicine containing drugs on Drugs-About.com: https://drugs-about.com/ing/colchicine.html
  • Colchicine for sale on Pharma Doctor (revised December 2021): https://pharma-doctor.com/colchicine.html
  • Colcrys (Colchicine) USP tablets for oral use official prescribing information and medication guide from the U.S. FDA (revised 11/2012): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Colcrys (Colchicine) tablets prescribing information from Takeda pharmaceutical company: https://www.takeda.com/en-us/what-we-do/product-portfolio/
  • Colgout (Colchicine) 500 mcg tablets product information from The Therapeutic Goods Administration (revised 28 August 2020): https://www.ebs.tga.gov.au/ebs/picmi/...
  • Wockhardt Colchicine 500 mcg tablets package information leaflet from Medicines.org.uk (revised 07/2019): https://www.medicines.org.uk/emc/files/pil.6415.pdf

    Revised: December 2021



    Home | About | Pain Treatment | Resources | Contact Us

    Copyright © 2010 - 2021 Coastal Interventional Pain Associates. All Rights Reserved.